FDA grants accelerated approval to Breyanzi (lisocabtagene maraleucel) for follicular lymphoma (Catapult's regulatory round-up - May 2024)
Year: 2024
Type: other
Abstract: On 15 May 2024, the FDA granted accelerated approval to lisocabtagene maraleucel for adults with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy. Please find further information here. Published on the 5th of June in Catapult's regulatory round-up for May 2024.
Source: OpenEdition (OpenEdition)
DOI: 10.58079/12m75
Author: Adelage
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6918030155
Cites:
Cited by:
Related to: